Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
20C/L452R
B.1.427/B.1.429
COVID-19
L452R mutation
SARS-CoV-2
antibody neutralization
genomic epidemiology
molecular dating
pseudovirus infectivity studies
spike protein
variant of concern
viral whole-genome sequencing
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
24 06 2021
24 06 2021
Historique:
received:
03
03
2021
revised:
02
04
2021
accepted:
15
04
2021
pubmed:
16
5
2021
medline:
2
7
2021
entrez:
15
5
2021
Statut:
ppublish
Résumé
We identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the western United States. Named B.1.427/B.1.429 to denote its two lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced cases from September 2020 to January 2021, showing 18.6%-24% increased transmissibility relative to wild-type circulating strains. The variant carries three mutations in the spike protein, including an L452R substitution. We found 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation common to variants B.1.1.7, B.1.351, and P.1. Antibody neutralization assays revealed 4.0- to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California exhibiting decreased antibody neutralization warrants further investigation.
Identifiants
pubmed: 33991487
pii: S0092-8674(21)00505-5
doi: 10.1016/j.cell.2021.04.025
pmc: PMC8057738
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3426-3437.e8Subventions
Organisme : NCPDCID CDC HHS
ID : U50 CI000498
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests C.Y.C. receives support for SARS-CoV-2 research unrelated to this study from Abbott Laboratories and Mammoth Biosciences. The other authors declare no competing interests.
Références
Lancet Microbe. 2020 Jul;1(3):e99-e100
pubmed: 32835336
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Lancet Microbe. 2020 Oct;1(6):e229-e230
pubmed: 32838349
EMBO J. 2019 Feb 15;38(4):
pubmed: 30643021
J Immunol Methods. 2005 Jun;301(1-2):21-30
pubmed: 15894326
Nature. 2021 Apr;592(7852):122-127
pubmed: 33636719
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Cell. 2021 May 13;184(10):2587-2594.e7
pubmed: 33861950
J Gen Virol. 2020 Nov;101(11):1156-1169
pubmed: 32821033
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Curr Biol. 2020 Aug 3;30(15):R849-R857
pubmed: 32750338
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Syst Biol. 2018 Sep 1;67(5):901-904
pubmed: 29718447
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:157-161
pubmed: 32869006
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
JAMA. 2021 Apr 6;325(13):1324-1326
pubmed: 33571356
PLoS Comput Biol. 2019 Apr 8;15(4):e1006650
pubmed: 30958812
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
BMJ. 2021 Feb 5;372:n359
pubmed: 33547053
Mol Biol Evol. 2012 Aug;29(8):1969-73
pubmed: 22367748
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Nat Protoc. 2017 Jun;12(6):1261-1276
pubmed: 28538739
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
J Mol Biol. 2020 Sep 4;432(19):5212-5226
pubmed: 32710986
Science. 2020 Jul 31;369(6503):582-587
pubmed: 32513865
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Bioinformatics. 2012 Jun 15;28(12):1647-9
pubmed: 22543367
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
Cell Mol Immunol. 2021 Apr;18(4):1061-1063
pubmed: 33633321
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
Diagn Microbiol Infect Dis. 2020 Nov;98(3):115130
pubmed: 32711184
Nat Commun. 2021 Jan 4;12(1):63
pubmed: 33397909
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Brief Bioinform. 2021 Mar 22;22(2):1239-1253
pubmed: 33006605
Viruses. 2020 May 06;12(5):
pubmed: 32384820
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
Lancet. 2021 Mar 13;397(10278):952-954
pubmed: 33581803
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Cell Stem Cell. 2020 Dec 3;27(6):876-889.e12
pubmed: 33232663